Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharmather Hldgs Ltd (PHRM.CN)

Pharmather Hldgs Ltd (PHRM.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 5,916
  • Shares Outstanding, K 91,019
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,526 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 3.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.04
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 01/29/26
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0600 +8.33%
on 04/02/26
0.1000 -35.00%
on 03/03/26
-0.0100 (-13.33%)
since 03/02/26
3-Month
0.0600 +8.33%
on 04/02/26
0.1050 -38.10%
on 01/06/26
-0.0350 (-35.00%)
since 01/02/26
52-Week
0.0600 +8.33%
on 04/02/26
0.7700 -91.56%
on 08/11/25
-0.1450 (-69.05%)
since 04/02/25

Most Recent Stories

More News
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher CEO Publishes Letter to Shareholders

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
Upcoming Meeting Dates - November 3, 2025

Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - The following is a list of Upcoming Meeting Dates for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service...

KEC.TO : 24.73 (+0.12%)
SUP.VN : 2.590 (+3.60%)
FMT.VN : 10.500 (-0.10%)
BARU.VN : 0.040 (unch)
SPN.VN : 0.055 (unch)
ESBL.VN : 0.145 (-6.45%)
GRDM.VN : 0.125 (+4.17%)
VGD.VN : 0.175 (-2.78%)
ESAU.CN : 0.5400 (-1.82%)
NTE.VN : 0.065 (+8.33%)
PRR.CN : 0.0750 (unch)
BY.CN : 0.0450 (unch)
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoingToronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher...

PHRM.CN : 0.0650 (unch)
PHRRF : 0.0470 (-6.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch and others.

See More

Key Turning Points

3rd Resistance Point 0.0717
2nd Resistance Point 0.0683
1st Resistance Point 0.0667
Last Price 0.0650
1st Support Level 0.0617
2nd Support Level 0.0583
3rd Support Level 0.0567

See More

52-Week High 0.7700
Fibonacci 61.8% 0.4988
Fibonacci 50% 0.4150
Fibonacci 38.2% 0.3312
Last Price 0.0650
52-Week Low 0.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.